As part of AbCheck’s global growth plans and in support of our valued multinational clients, AbCheck is expanding its presence in the United States
PLZEN, Czech Republic and SAN DIEGO (PRWEB) October 30, 2018
AbCheck s.r.o., a leader in providing antibody drug discovery, engineering and optimization services to the biotech and pharmaceutical industry, is pleased to announce its expansion and United States presence with the incorporation of AbCheck, Inc. In conjunction with the expansion, AbCheck has hired Shelly Adams, Vice President of Business Development to lead the commercial efforts within the United States.
“As part of AbCheck’s global growth plans and in support of our valued multinational clients, AbCheck is expanding its presence in the United States, and delighted to have Shelly leading our commercial efforts,” said Dr. Volker Lang, Managing Director of AbCheck s.r.o. “The addition of Shelly is an important step in completing our new brand identity reflecting the positive changes and growth in the organization and dedication to providing a superior service and technological advantage for our customers all over the world.”
Shelly Adams is a seasoned marketing and sales executive bringing more than 25 years of proven experience in the medical device, biotech, pharmaceutical and contract manufacturing industry to AbCheck. Prior to joining AbCheck, Shelly has worked for Abzena, Gallus BioPharmaceuticals and Avecia Biologics in the Contract Development Manufacturing Organization (CDMO) marketplace.
“I am very excited to join the AbCheck team and help the organization grow and realize its vision and mission,” added Shelly Adams. “AbCheck has an exceptional and experienced staff, uses cutting-edge technologies and excellent facilities to meet and exceed the pharma and biotech industry standards for developing new drug candidates.”
For additional information on AbCheck’s contract discovery and optimization services with monoclonal antibodies, visit https://abcheckantibodies.com, or email us at info(at)abcheckantibodies.com or bd(at)abcheckantibodies.com.
AbCheck s.r.o. discovers and optimizes human antibodies leveraging several proprietary platforms including in vitro and in vivo technologies as a service to our partners. We use phage/yeast display libraries (AbSieve™), mass humanization and antibody optimization (AbAccel™) to provide high quality leads. Our technology platform can be used in conjunction with all antibody designs and allows selection of optimized leads from a huge number of variants. Flexibly adapting to our partners’ needs, we offer a variety of business models, including deals without royalties. AbCheck has proven its capabilities in multiple partnerships throughout the US and Europe. AbCheck is a wholly owned subsidiary of Affimed GmbH. For more information, please visit https://abcheckantibodies.com.